Does imaging αvβ3 integrin expression with PET detect changes in angiogenesis during bevacizumab therapy?

Journal of Nuclear Medicine

Volumn 55, Issue 11, 2014, Pages 1878-1884

  Rylova, Svetlana N ^a,b   Barnucz, Enikö ^b   Fani, Melpomeni ^b   Braun, Friederike ^b   Werner, Martin ^a,b   Lassmann, Silke ^a,b,c   Maecke, Helmut R ^b   Weber, Wolfgang A ^d  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b UNIVERSITY OF FREIBURG   (Germany)

^c UNIVERSITY OF FREIBURG   (Germany)

^d MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Angiogenesis; v integrin; PET; normalization; bevacizumab

Indexed keywords

ANGIOGENESIS INHIBITOR; ARGINYLGLYCYLASPARTIC ACID; BEVACIZUMAB; GALLIUM 68; NODAGA C(RGDFK) GA 68; RADIOPHARMACEUTICAL AGENT; SODIUM CHLORIDE; TETRAXETAN; TETRAXETAN GA 68; UNCLASSIFIED DRUG; VITRONECTIN RECEPTOR; 1-(1,3-CARBOXYPROPYL)-4,7-CARBOXYMETHYL-1,4,7-TRIAZACYCLONONANE; ACETIC ACID DERIVATIVE; ARGINYL-GLYCYL-ASPARTIC ACID; GALLIUM; MONOCLONAL ANTIBODY; OLIGOPEPTIDE; PEPTIDE; SINGLE HETEROCYCLIC RINGS;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC THERAPY; ARTICLE; BLOOD VESSEL; CANCER INHIBITION; CANCER TRANSPLANTATION; CAPILLARY DENSITY; COMPUTED TOMOGRAPHY SCANNER; CONTROLLED STUDY; DRUG PENETRATION; DRUG TUMOR LEVEL; FEMALE; HUMAN; HUMAN CELL; IMAGING; ISOTOPE LABELING; MOUSE; NONHUMAN; NUDE MOUSE; PET SCANNER; POSITRON EMISSION TOMOGRAPHY; PROTEIN EXPRESSION; SQUAMOUS CELL CARCINOMA CELL LINE; TUMOR NECROSIS; TUMOR VASCULARIZATION; TUMOR XENOGRAFT; ALGORITHM; ANIMAL; BAGG ALBINO MOUSE; CARCINOMA, SQUAMOUS CELL; CHEMISTRY; DIAGNOSTIC USE; METABOLISM; MICROCIRCULATION; NECROSIS; NEOVASCULARIZATION (PATHOLOGY); PERMEABILITY; SCINTISCANNING; TIME; TUMOR CELL LINE;

ACETATES; ALGORITHMS; ANGIOGENESIS INHIBITORS; ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; FEMALE; GALLIUM RADIOISOTOPES; HETEROCYCLIC COMPOUNDS, 1-RING; HUMANS; INTEGRIN ALPHAVBETA3; MICE; MICE, INBRED BALB C; MICE, NUDE; MICROCIRCULATION; NECROSIS; NEOPLASM TRANSPLANTATION; NEOVASCULARIZATION, PATHOLOGIC; OLIGOPEPTIDES; PEPTIDES; PERMEABILITY; POSITRON-EMISSION TOMOGRAPHY; TIME FACTORS;

EID: 84910618556     PISSN: 01615505     EISSN: 2159662X     Source Type: Journal    
DOI: 10.2967/jnumed.114.137570     Document Type: Article

References (25)

1. Ferrara N, Kerbel RS. Angiogenesis as a therapeutic target. Nature. 2005; 438:967-974.
2. Jayson GC, Hicklin DJ, Ellis LM. Antiangiogenic therapy: evolving view based on clinical trial results. Nat Rev Clin Oncol. 2012;9:297-303.
3. Sennino B, McDonald DM. Controlling escape from angiogenesis inhibitors. Nat Rev Cancer. 2012;12:699-709.
4. Lambrechts D, Lenz HJ, de Haas S, Carmeliet P, Scherer SJ. Markers of response for the antiangiogenic agent bevacizumab. J Clin Oncol. 2013;31:1219-1230.
5. Ehling J, Lammers T, Kiessling F. Non-invasive imaging for studying antiangiogenic therapy effects. Thromb Haemost. 2013;109:375-390.
6. Chen K, Cai W, Li ZB, Wang H, Chen X. Quantitative PET imaging of VEGF receptor expression. Mol Imaging Biol. 2009;11:15-22.
7. Zhang Y, Yang Y, Hong H, Cai W. Multimodality molecular imaging of CD105 (Endoglin) expression. Int J Clin Exp Med. 2011;4:32-42.
8. Brooks PC, Clark RA, Cheresh DA. Requirement of vascular integrin alpha v beta 3 for angiogenesis. Science. 1994;264:569-571.
9. Brooks PC, Montgomery AM, Rosenfeld M, et al. Integrin avb3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell. 1994;79:1157-1164.
10. Desgrosellier JS, Cheresh DA. Integrins in cancer: biological implications and therapeutic opportunities. Nat Rev Cancer. 2010;10:9-22.
11. Haubner R, Beer AJ, Wang H, Chen X. Positron emission tomography tracers for imaging angiogenesis. Eur J Nucl Med Mol Imaging. 2010;37:S86-S103.
12. Battle MR, Goggi JL, Allen L, Barnett J, Morrison MS. Monitoring tumor response to antiangiogenic sunitinib therapy with 18F-fluciclatide, an 18Flabeled aVb3-integrin and aVb5-integrin imaging agent. J Nucl Med. 2011;52: 424-430.
13. Dumont RA, Deininger F, Haubner R, Maecke HR, Weber WA, Fani M. Novel 64Cu-And 68Ga-labeled RGD conjugates show improved PET imaging of avb3 integrin expression and facile radiosynthesis. J Nucl Med. 2011;52:1276-1284.
14. Haubner R, Weber WA, Beer AJ, et al. Noninvasive visualization of the activated avb3 integrin in cancer patients by positron emission tomography and [18F] galacto-RGD. PLoS Med. 2005;2:e70.
15. Beer AJ, Grosu AL, Carlsen J, et al. [18F]galacto-RGD positron emission tomography for imaging of avb3 expression on the neovasculature in patients with squamous cell carcinoma of the head and neck. Clin Cancer Res. 2007;13:6610-6616.
16. Beer AJ, Niemeyer M, Carlsen J, et al. Patterns of avb3 expression in primary and metastatic human breast cancer as shown by 18F-galacto-RGD PET. J Nucl Med. 2008;49:255-259.
17. Schnell O, Krebs B, Carlsen J, et al. Imaging of integrin avb3 expression in patients with malignant glioma by [18F] galacto-RGD positron emission tomography. Neuro-oncol. 2009;11:861-870.
18. Tewari KS, Sill MW, Long HJ 3rd, et al. Improved survival with bevacizumab in advanced cervical cancer. N Engl J Med. 2014;370:734-743.
19. Argiris A, Karamouzis MV, Gooding WE, et al. Phase II trial of pemetrexed and bevacizumab in patients with recurrent or metastatic head and neck cancer. J Clin Oncol. 2011;29:1140-1145.
20. Fury MG, Lee NY, Sherman E, et al. A phase 2 study of bevacizumab with cisplatin plus intensity-modulated radiation therapy for stage III/IVB head and neck squamous cell cancer. Cancer. 2012;118:5008-5014.
21. Plow EF, Meller J, Byzova TV. Integrin function in vascular biology: a view from 2013. Curr Opin Hematol. 2014;21:241-247.
22. Dumont RA, Hildebrandt I, Su H, et al. Noninvasive imaging of avb3 function as a predictor of the antimigratory and antiproliferative effects of dasatinib. Cancer Res. 2009;69:3173-3179.
23. Carmeliet P, Jain RK. Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases. Nat Rev Drug Discov. 2011;10:417-427.
24. Chatterjee S, Wieczorek C, Schottle J, et al. Transient antiangiogenic treatment improves delivery of cytotoxic compounds and therapeutic outcome in lung cancer. Cancer Res. 2014;74:2816-2824.
25. Yang M, Gao H, Yan Y, et al. PET imaging of early response to the tyrosine kinase inhibitor ZD4190. Eur J Nucl Med Mol Imaging. 2011;38:1237-1247.